Clinical Trial Update: Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating carfilzomib and melphalan as conditioning therapy before stem cell transplant in multiple myeloma patients; study completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• Melphalan (Melphalan)

Snippet

Sponsor: Mayo Clinic | Conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-09-01